The pandemic put a spotlight on the biotech and pharmaceutical business as their shares reached new heights in the aftermath.
The major pharmaceutical companies have performed well through 2022, even as other industries struggle in the context of the rising cost of living and the rising cost of living.
A broad exposure to the industry allows investors to profit from the increasing demand in the long term for healthcare services.
Pharmaceutical industry seen significant changes in the last few years.
Although the Covid vaccines made news the years of research beginning to bear fruit for major players such as AstraZeneca as well as GlaxoSmithKline.
However, with the threat of a recession on the horizon, can pharmaceutical companies be in a position to maintain their growth? It could be an ideal moment to buy biotech companies that have seen their stock prices plummet?
Its Covid vaccine has increased AstraZeneca’s global visibility significantly. in February, the company reported the highest revenue quarter ever, comprising $1.8billion due to the Covid vaccine as well as the sales of the acquisition of $39 billion of Alexion. The company also raised its dividend by the highest amount in the past decade.
AstraZeneca is currently the second-largest FTSE 100 company by market value after having doubled its share price over five years. It’s an extremely popular investment for income funds like Artemis as well as Columbia Threadneedle Equity Income fund in the UK.
The big pharma companies represented by FTSE 100’s constituents AstraZeneca as well as GlaxoSmithKline have been performing well in the market’s overall slump this year. The shares of both companies are up 28 percent and 8 percent, each, for the year-to-date according to Garry White, Charles Stanley’s chief investment analyst.
The sales of ‘Covid-19′ are slowing down, however the ease of pandemic restrictions has boosted sales for other vaccines. Sales of cancer drugs are increasing and the main players have plenty of pipelines for possible new products under development.’
GSK has also been performing well . In the first quarter, sales increased by 32 percent and operating profits grew by 65 per cent.
But it’s got an uncertain road ahead following selling its business for consumers Haleon which is been listed in the London Stock Exchange.
The demerger is likely to alter the form of GSK to become an independent pharma group. Its business in consumer healthcare was generally predictable, with a steady income , but its shares have been crashing since Haleon’s debut.
Although Haleon’s trading on its opening day was on the lower than expected For investors seeking an income that is more steady, it may prove to be a worthwhile investment.
Fundamentally, this is a desirable industry and business to take exposure to due to its defensive nature at an era when market volatility is causing disruption according to Chris Beckett, head of equity research at Quilter Cheviot.
The business has established strong brand names and market positions in the areas of oral health as well as digestive health, pain relief as well as respiratory health, vitamins and digestive health. There is no reason why these can’t be sustained.’
What is the best way to ensure that pharmaceuticals are recession-proof?
In general , demand from investors has been fairly resilient in spite of the economic recession, since they’re considered to be safer and have a higher level of security.
Ailsa Craig, the joint lead investment manager for International Biotechnology Trust says: “In times of economic recession, healthcare and food are typically a top priority for people, and the need for medical treatment is not diminished. Actually, the percentage of over 65-year aged who are likely to require medical attention is expected to double in the coming years.
So, while coverage for insurance could be reduced and causing some pressure on prices, especially for non-essential treatment, overall market sales in the pharmaceutical sector, especially of those that treat serious ailments, are not likely to be significantly affected by a slowdown to economic expansion.’
Conglomerates in the field of healthcare have traditionally been an amalgamation of diverse companies that include pharmaceuticals, consumer health and animal health, while some could even include medical device business.
There is a consensus that a large group of people will provide you with an even more secure portfolio. Consumer health is a defensive… Pharmaceuticals may appear to be defensive, but you’ll need to purchase more products since it isn’t exclusive. There are more troughs and peaks, says Andrew Duncan, senior equity analyst at Killick.
How can investors determine which ones are best investments to make?
An investor should search for a company that has a good reputation for Research and Development (R&D) and a solid pipeline, and a track record of providing that pipeline Duncan says. Duncan. You must have a lot of eggs in your basket.
We look at the general direction of the travel… We are looking for companies to provide into the realm of R&D. Tools and life sciences field… there’s need for services, but we’re not dependent on the performance of one particular item or test.’
Companies set to benefit from this market include the US-listed Thermofisher that specializes in research and has recently acquired an enterprise for clinical trials.
Is it the right moment to invest in biotech stocks that are volatile?
Biotech companies, situated at the crossroads between tech and pharma were also the winners of the vaccine bounce.
After soaring in 2020, shares of biotech companies have plummeted in the wake of the shift away from biotech stocks that are growing. It is worth noting that the Nasdaq Biotechnology Index has experienced an unstable three years, with its highest in 2021, followed by an extended decline.
The overshooting and correction of performance is typical of biotech, but overall, the trajectory has been positive, with an outperformance compared to those of UK FTSE 100 over the last three years Craig says. Craig.
International Biotechnology Trust is unusual in the world of growth-focused investment trusts by paying a significant dividend. The current yield of 5.01 percent.
The trust has a wide range of companies, most of with a drug approval currently on the market. This includes Horizon Therapeutics, Incite and Neurocrine.
Although biotech can be an exciting market for investors, it’s highly risky. Investors who buy individual stocks are susceptible to extreme risks.
White states: “The present problem facing companies operating at the forefront of the biotech industry is as with researchers and developers in the more conventional technology sectors, they require substantial capital to begin in their R&D.
The revenues they earn from their products, despite the fact that they could be significant but are not likely to be realized in the near future. It’s all about “jam tomorrow’.
“This type of business is dependent on borrowing, and higher cost of borrowing today will mean less profit realised over the long term.
The sum of the interest that they be required to pay now has an impact directly on the value of these companies in models used by City analysts. When interest rates rise the forecasts for future earnings and price expectations are reduced.’
Biotech’s hottest product Oxford Nanopore has certainly suffered since its debut on the market in the year 2000. It’s dropped 32 percent since the date of its debut and has dropped 56 per cent from the time of its listing to date.
In March, it announced that its the annual loss jumped to more than PS100million due to costs related with its IPO and share-based payment. The company also suffered following the expiration of an agreement in partnership with the Department of Health and Social Care which provided rapid Covid tests.
White continues: “The future of healthcare is certain to be positive, with promising developments in areas such as the use of mRNA-based vaccinations, gene therapy and monoclonal antibody monoclonal.
The general mood towards the biotech industry is in a cyclical fashion and the pressure to structurally improve the less sexy section remains significant.
The rising rates of interest, inflation and geopolitical uncertainties add to the negativity surrounding these assets due to the time frame they have to earn profits make them long-lasting and risky investments.
Negative influences that could affect the outlook for the sector are likely to be present for a while. It is expected to be the case that Big Pharma, with its various product portfolios and numerous sources of revenue, will continue be the preferred choice of investors to invest for a while. In the present, safety is paramount.’
© All Rights Reserved.